



Prof. Dr. Michael Weller

Kontakt

Prof. Dr. Michael Weller
Switzerland

Publikationen (40)

Mastall M, Roth P, Bink A, Maranta A, Läubli H, Hottinger A, Hundsberger T, Migliorini D, Ochsenbein A, Seystahl K, Imbach L, Hortobágyi T, Held L, Weller M, Wirsching H. A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol. *BMC cancer* 2024; 24:82.

Padevit L, Vasella F, Friedman J, Mutschler V, Jenkins F, Held U, Rushing E, Wirsching H, Weller M, Regli L, Neidert M. A prognostic model for tumor recurrence and progression after meningioma surgery: preselection for further molecular work-up. *Front Oncol* 2023; 13:1279933.

Stadler C, Gramatzki D, Le Rhun E, Hottinger A, Hundsberger T, Roelcke U, Läubli H, Hofer S, Seystahl K, Wirsching H, Weller M, Roth P. Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older. *Neurooncol Pract* 2023; 11:132-141.

Leske H, Camenisch Gross U, Hofer S, Neidert M, Leske S, Weller M, Lehnick D, Rushing E. MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value. *Acta Neuropathol Commun* 2023; 11:139.

Medici G, Freudenmann L, Velz J, Wang S, Kapolou K, Paramasivam N, Mühlenbruch L, Kowalewski D, Vasella F, Bilich T, Frey B, Dubbelaar M, Patterson A, Zeitlberger A, Silginer M, Roth P, Weiss T, Wirsching H, Krayenbühl N, Bozinov O, Regli L, Rammensee H, Rushing E, Sahm F, Walz J, Weller M, Neidert M. A T-cell antigen atlas for meningioma: novel options for immunotherapy. *Acta Neuropathol* 2023; 146:173-190.

Naghavian R, Faigle W, Oldrati P, Wang J, Toussaint N, Qiu Y, Medici G, Wacker M, Freudenmann L, Bonté P, Weller M, Regli L, Amigorena S, Rammensee H, Walz J, Brugger S, Mohme M, Zhao Y, Sospedra M, Neidert M, Martin R. Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma. *Nature* 2023; 617:807-817.

Wang J, Weiss T, Neidert M, Toussaint N, Naghavian R, Sellés Moreno C, Foegen M, Tomas Ojer P, Medici G, Jelcic I, Schulz D, Rushing E, Dettwiler S, Schrörs B, Shin J, McKay R, Wu C, Lutterotti A, Sospedra M, Moch H, Greiner E, Bodenmiller B, Regli L, Weller M, Roth P, Martin R. Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma. *Clin Cancer Res* 2022; 28:5368-5382.

Weber L, Padevit L, Müller T, Velz J, Vasella F, Voglis S, Gramatzki D, Weller M, Regli L, Sarnthein J, Neidert M. Association of perioperative adverse events with subsequent therapy and overall survival in patients with WHO grade III and IV gliomas. *Front Oncol* 2022; 12:959072.

Voglis S, Schaller V, Müller T, Gönel M, Winklhofer S, Mangana J, Dummer R, Serra C, Weller M, Regli L, Le Rhun E, Neidert M. Maximal surgical tumour load reduction in immune-checkpoint inhibitor naïve patients with melanoma brain metastases correlates with prolonged survival. *Eur J Cancer* 2022; 175:158-168.

Akeret K, Vasella F, Staartjes V, Velz J, Müller T, Neidert M, Weller M, Regli L, Serra C, Krayenbühl N. Anatomical phenotyping and staging of brain tumours. *Brain* 2022; 145:1162-1176.

German Consortium on Aggressive Meningiomas (KAM), Ratliff M, Neidert M, Wirsching H, Harter P, Unterberg A, Herold-Mende C, Jungwirth G, Etminan N, Lamszus K, Westphal M, Hänggi D, Jungk C, Mawrin C, Platten M, Snuderl M, Sahm F, von Deimling A, Preusser M, Weller M, Wick W, Acker T, Reifenberger G, Jones D, Pfister S, Frank S, Hench J, Brandner S, Aldape K, Sen C, Golfinos J, Serrano J, Stein M, Dohmen H, Reuss D, Dogan H, Patel A, Blume C, Euskirchen P, Sill M, Schrimpf D, Berghoff A, Sievers P, Hielscher T, Stichel D, Reinhardt A, Suwala A, Grady C, Jones T, Bridges L, Greenway F, Leu S, Jaunmuktane Z, Schittenhelm J, Ketter R, Bewerunge-Hudler M, Rushing E, Ricklefs F, Baumgarten P, Wefers A, Maas S. Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. *J Clin Oncol* 2021; 39:3839-3852.

Hofer S, Baumert B, Läubli H, Gramatzki D, Reinert M, Pesce G, Schucht P, Frank I, Lehnick D, Weiss T, Wirsching H, Wolpert F, Roth P, Eggenberger N, Pflugshaupt T, Keller K, Imbach L, Roelcke U, Hutter G, Hundsberger T, Hertler C, Le Rhun E, Vasella F, Cordier D, Neidert M, Hottinger A, Migliorini D, Weller M. Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM). *Swiss Med Wkly* 2021; 151:w20501.

Marcu A, Walz J, Velz J, Moch H, Regli L, Silginer M, Weller M, Löffler M, Erhard F, Schlosser A, Kohlbacher O, Stevanovic S, Rammensee H, Kapolou K, Martin R, Hauri-Hohl M, Bichmann L, Kuchenbecker L, Kowalewski D, Freudenmann L, Backert L, Mühlenbruch L, Szolek A, Lübke M, Wagner P, Engler T, Matovina S, Wang J, Neidert M. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. *J Immunother Cancer* 2021; 9

Wirsching H, Tabatabai G, Ochsenbein A, Roth P, Remonda L, Conen K, Caparrotti F, von Moos R, Hottinger A, Hundsberger T, Weller J, Roelcke U, Weller M. MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. *Clin Cancer Res* 2020; 27:179-188.

von Achenbach C, von Deimling A, Schneider H, Lawhon T, Rushing E, Neidert M, Sievers P, Wang S, Sahm F, Le Rhun E, Weller M. Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02. *Transl Oncol* 2020; 13:100852.

Sievers P, Etminan N, Ratliff M, Herold-Mende C, Pfister S, Jones D, Weller M, Harter P, Wick W, Preusser M, von Deimling A, Westphal M, Lamszus K, Reifenberger G, Hielscher T, Schrimpf D, Stichel D, Reuss D, Berghoff A, Neidert M, Wirsching H, Mawrin C, Ketter R, Paulus W, Sahm F. CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. *Acta Neuropathol* 2020; 140:409-413.

Roth P, Hofer S, Pesce G, Roelcke U, Mamot C, Reinert M, Schucht P, Läubli H, Hundsberger T, Hottinger A, Weller M. A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. *Swiss Med Wkly* 2020; 150:w20256.

Friebel E, Neidert M, Tugues S, Greter M, Weller M, Regli L, Rushing E, Utz S, Núñez N, Unger S, Kapolou K, Becher B. Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invasive Leukocytes. *Cell* 2020; 181:1626-1642.e20.

Wolpert F, Preusser M, Le Rhun E, Andratschke N, Neidert M, Roth P, Löb R, Lareida A, Grossenbacher B, Berghoff A, Weller M. Venous thromboembolic events in patients with brain metastases: the PICOS score. *Eur J Cancer* 2020; 134:75-85.

Gramatzki D, Rogers J, Neidert M, Hertler C, Le Rhun E, Roth P, Weller M. Antidepressant drug use in glioblastoma patients: an epidemiological view. *Neurooncol Pract* 2020; 7:514-521.

Wolpert F, Le Rhun E, Imbach L, Poryazova R, Roth P, Neidert M, Grossenbacher B, Terziev R, Lareida A, Weller M. Risk factors for the development of epilepsy in patients with brain metastases. *Neuro Oncol* 2020; 22:718-728.

Zhu Y, Christiansen A, Fritz C, Rupp N, Poyet C, Rushing E, Weller M, Roth P, Haralambieva E, Hofer S, Chen C, Jochum W, Gao X, Teng X, Chen L, Zhong Q, Wild P, Aebersold R, Ljubicic J, Rutishauser D, Schmid M, Weiss T, Zhang Q, Sun R, Wang B, Yi X, Wu Z, Gao H, Cai X, Ruan G, Zhu T, Xu C, Lou S, Yu X, Gillet L, Blattmann P, Saba K, Fankhauser C, Guo T. High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification. *Mol Oncol* 2019; 13:2305-2328.

Paramasivam N, Beck K, Brehmer S, Urbschat S, Seiz-Rosenhagen M, Hänggi D, Herold-Mende C, Ketter R, Eils R, Ram Z, Pfister S, Wick W, Weller M, Grossmann R, von Deimling A, Schlesner M, Bewerunge-Hudler M, Schick M, Hübschmann D, Toprak U, Ishaque N, Neidert M, Schrimpf D, Stichel D, Reuss D, Sievers P, Reinhardt A, Wefers A, Jones D, Gu Z, Werner J, Uhrig S, Wirsching H, Sahm F. Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. *Acta Neuropathol* 2019; 138:295-308.

Neurooncology Working Group of the German Cancer Society, Simon M, Tonn J, Stummer W, Schaub C, Weller J, Kebir S, Schäfer N, Stuplich M, Vatter H, Misch M, Keil V, Nelles M, Glas M, Coch C, Pietsch T, Hattingen E, Schmid M, Fimmers R, Weller M, Wick W, Coenen M, Urbach H, Vajkoczy P, Galldiks N, Bullinger L, Goldbrunner R, Grauer O, Krex D, Kortmann R, Hau P, Sabel M, Schlegel U, Steinbach J, Mack F, Tzaridis T, Schnell O, Bähr O, Renovanz M, Weyerbrock A, Brehmer S, Suchorska B, Schmidt-Graf F, Ringel F, Kowalski T, Tabatabai G, Seidel C, Uhl M, Herrlinger U. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. *Lancet* 2019; 393:678-688.

Wolpert F, Preusser M, Kaufmann P, Reyns N, Roth P, Frauenfelder T, Dummer R, Stahel R, Stupp R, Neidert M, Regli L, Andratschke N, Leske H, Petyt G, Füreder L, Rushing E, Berghoff A, Weller M, Le Rhun E. Diagnostic value of F-fluorodesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. *Eur J Cancer* 2018; 96:64-72.

Katz L, Baumgarten P, Herold-Mende C, Wick W, Harter P, Weller M, von Deimling A, Snuderl M, Sen C, Wirsching H, Neidert M, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R, Wu P, Golfinos J, Reuss D, Sahm F. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. *Acta Neuropathol* 2018; 135:955-963.

Neidert M, Rammensee H, Henschler R, Lamszus K, Westphal M, Roth P, Regli L, Stevanovic S, Weller M, Wolpert F, Walz J, Kowalewski D, Silginer M, Kapolou K, Backert L, Freudenmann L, Peper J, Marcu A, Wang S, Eisele G. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. *Acta Neuropathol* 2018; 135:923-938.

Beier D, Proescholdt M, Reinert C, Pietsch T, Jones D, Pfister S, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs S, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann R, Bogdahn U, Hau P. Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). *Neuro Oncol* 2018; 20:400-410.

Hundsberger T, Weller M. Bevacizumab: Zankapfel der Glioblastomtherapie. *Praxis (Bern 1994)* 2017; 106:415-420.

Filli L, Weller M, Petersen J, Philipp G, Killeen T, Sutter T, Weller D, Lorincz L, Reuter K, Kapitza S, Zörner B, Linnebank M. Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis. *Neurology* 2017; February

Wick W, Golfopoulos V, Frenel J, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Roth P, Stupp R, Gorlia T, Bady P, Platten M, van den Bent M, Taphoorn M, Steuve J, Brandes A, Hamou M, Wick A, Kosch M, Weller M, Hegi M. Phase II Study of Radiotherapy and Temozolomide versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). *Clin Cancer Res* 2016; 22:4797-4806.

Wirsching H, Morel C, Gmür C, Neidert M, Baumann C, Valavanis A, Rushing E, Krayenbühl N, Weller M. Predicting outcome of epilepsy after meningioma resection. *Neuro Oncol* 2015; 18:1002-10.

Wolpert F, Weller M, Westphal M, Lamszus K, Neidert M, Roth P, Deenen R, Florea A, Reifenberger G, Happold C, Eisele G. Interferon- β Modulates the Innate Immune Response against Glioblastoma Initiating Cells. *PloS one* 2015; 10:e0139603.

Korfel A, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Mergenthaler H, Hundsberger T, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Weller M. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. *Neurology* 2015; 84:1242-8.

Hundsberger T, Tonder M, Hottinger A, Brügge D, Roelcke U, Putora P, Stupp R, Weller M. Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients. *J Neurooncol* 2014; 118:321-328.

Mohme M, Neidert M, Regli L, Weller M, Martin R. Immunological challenges for peptide-based immunotherapy in glioblastoma. *Cancer Treat Rev* 2013; 40:248-58.

Seystahl K, Wiestler B, Hundsberger T, Happold C, Wick W, Weller M, Wick A. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. *Eur Neurol* 2012; 69:95-101.

Hofer S, Wick W, Zander T, Weder P, Roelcke U, Pichler J, Ochsenbein A, Marosi C, Lemke D, Huber U, Hottinger A, Greil R, Elandt K, Weller M. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. *Acta Oncol* 2011; 50:630-5.

Thiel E, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Leithäuser M, Mergenthaler H, Hundsberger T, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Weller M. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. *Lancet Oncol* 2010; 11:1036-47.

Herrlinger U, Reifenberger G, Bamberg M, Sommer C, Tan T, Meyermann R, Wick W, Hundsberger T, Steinbach J, Kortmann R, Blaschke B, Loeser S, Koch D, Rieger J, Weller M. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2006; 24:4412-7.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch